Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 347 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Test formulation Clear all
Completed Phase 1 Interventional

Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes

NCT07090824
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus
Interventions
Diluted Humalog U-200 Insulin, Diluted U-500 Humulin Insulin, Lyumjev U-100 Insulin, Boost Mixed Meal Test
Drug · Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability For Palbociclib Formulations

NCT02083640
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib Formulation Reference, Palbociclib Formulation Test
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design

NCT06369675
View directory record Official record
Conditions
Erythema
Interventions
MOB015B, 0.2% SLS, 0.9% Saline, MOB015B vehicle
Drug
Lead sponsor
Moberg Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use

NCT01204866
View directory record Official record
Conditions
Allergic Reactions
Interventions
Valortim and selected Components, Valortim and Selected Components
Biological · Drug
Lead sponsor
PharmAthene, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2010 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fasted, Healthy, Adult Subjects

NCT00944177
View directory record Official record
Conditions
Healthy
Interventions
Metformin HCl
Drug
Lead sponsor
Torrent Pharmaceuticals Limited
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 22, 2009 · Synced Sep 2, 2026, 4:00 PM EDT
Not listed Phase 1Phase 2 Interventional

Impact of CBD-Rich Oil on Aversive Memory Reconsolidation

NCT04726475
View directory record Official record
Conditions
Anxiety and Fear
Interventions
Interoceptive Aversive Memory Reactivation, Cannabidiol (CBD)-Rich Broad Spectrum Hemp Extract Oil, Placebo Oil
Behavioral · Dietary Supplement
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 2, 2026, 4:00 PM EDT
Suspended Phase 1 Interventional

2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML

NCT06626633
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
CRD3874
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 2, 2026, 4:00 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

NCT05201638
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
IMU-838 tablets, Placebo matching IMU-838 tablets
Drug
Lead sponsor
Immunic AG
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
2
States / cities
Altamonte Springs, Florida • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Bioavailability of Dutasteride Novel Formulation Form to the Soft Gel Capsule Form in Healthy Male Subjects

NCT01577693
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
dutasteride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548

NCT05455502
View directory record Official record
Conditions
Pain
Interventions
VX-548
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects

NCT06107205
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
TTYP01, Radicava, Radicava ORS
Drug
Lead sponsor
Shanghai Auzone Biological Technology Co., Ltd.
Industry
Eligibility
20 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Human Phototoxicity Test (823/2016)

NCT02962856
View directory record Official record
Conditions
Sunscreening Agents
Interventions
BAY987517, Untreated Skin
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid

NCT04309656
View directory record Official record
Conditions
Multi-drug Resistant Tuberculosis
Interventions
Pretomanid
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Astaxanthin Formulation Bioavailability

NCT02397811
View directory record Official record
Conditions
Bioavailability of Astaxanthin Formulations
Interventions
Enteric Coated Softgels, Liposomal astaxanthin, Standard Softgel, Astaxanthin Water Soluble Emulsion, Astaxanthin Water Dispersible Powder, Standard Softgel with Astaxanthin Gel
Dietary Supplement
Lead sponsor
Cyanotech Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder

NCT02350309
View directory record Official record
Conditions
Insomnia Disorder
Interventions
Lemborexant 5 mg, Lemborexant 10 mg, Lemborexant-matched placebo., Flurazepam 30 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Atlanta, Georgia • Crestview Hills, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 1 Interventional

A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma

NCT07433569
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/formoterol fumarate Aerosphere, Budesonide/formoterol fumarate pMDI
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
4 Years to 12 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
6
States / cities
Long Beach, California • Miami, Florida • Lafayette, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Azithromycin 600 Mg Tablets, Fasting

NCT00834756
View directory record Official record
Conditions
Healthy
Interventions
Azithromycin 600 mg Tablet, Zithromax® 600 mg Tablet
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Human Phototoxicity Test

NCT02751541
View directory record Official record
Conditions
Sunscreening Agents
Interventions
Sunscreen Sport Spray (BAY987519), Untreated Skin
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544

NCT07563894
View directory record Official record
Conditions
Healthy
Interventions
PF-07799933 tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fed, PF-07799933 film-coated tablets fasted, PF-07799933 film-coated tablets following rabeprazole pretreatment fasted
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants

NCT05525910
View directory record Official record
Conditions
Biological Availability, Healthy Participants
Interventions
Nirmatrelvir/ ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 2, 2026, 4:00 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants

NCT07610005
View directory record Official record
Conditions
Healthy
Interventions
Varegacestat Reference Formulation, Varegacestat Test Formulation
Drug
Lead sponsor
Immunome, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol

NCT05260359
View directory record Official record
Conditions
Sunburn
Interventions
6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation, 6% Bemotrizinol (BEMT) dispersion in petrolatum, Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT, Petrolatum vehicle, 0.9% Saline, Sodium Lauryl Sulfate 0.1% (SLS), Undosed patch
Drug · Other
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions

NCT05433896
View directory record Official record
Conditions
Pharmacokinetics, Drug Interactions
Interventions
Dasatinib ASD, Omeprazole 40 MG
Drug
Lead sponsor
Xspray Pharma AB
Industry
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2022 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sun Protection Factor Assay (341/2016)

NCT02995135
View directory record Official record
Conditions
Sunscreening Agents
Interventions
BAY987517, SFP Control
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Sep 2, 2026, 4:00 PM EDT